[1] 马金燕,杨勇,王昀. CAR-T的发展历程及实体瘤治疗难点. 药学研究, 2020, 39: 531-533.
[2] Park JH, Rivieve I, Gonen M, et al. Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia. N Engl J Med, 2018, 378: 449-459.
[3] Ma L, Dichwalkar T, Chang JY, et al. Enhanced CAR-T cell activity against solid tumors by vaccine boosting through the chimeric receptor. Science, 2019, 365: 162-168.
[4] Martinez M, Moon EK. CAR T Cells for Solid Tumors: New Strategies for Finding, Infiltrating, and Surviving in the Tumor Microenvironment. Front Immunol, 2019, 10: 1-21.
[5] Milliotou AN, Papadopoulou LC. CAR T-cell Therapy: A New Era in Cancer Immunotherapy. Curr Pharm Biotechno, 2018, 19: 5-18.
[6] Ravichandra A, Filliol A, Schwabe RF. Chimeric Antigen Receptor T Cells as Senolytic and Antifibrotic Therapy. Hepatology, 2021, 73: 1227-1229.
[7] He S, Sharpless NE. Senescence in Health and Disease. Cell, 2017, 169: 1000-1011.
[8] Zhang CY, Yuan WG, He P, et al. Liver fibrosis and hepatic stellate cells: Etiology, pathological hallmarks and therapeutic targets. World J Gastroenterol, 2016, 22: 10512-10522.
[9] Schnabl B, Purbeck CA, Choi YH, et al. Replicative senescence of activated human hepatic stellate cells is accompanied by a pronounced inflammatory but less fibrogenic phenotype. Hepatology, 2003, 37: 653-664.
[10] Amor C, Feucht J, Leibold J, et al. Senolytic CAR T cells reverse senescence-associated pathologies. Nature, 2020, 583: 127-132.
[11] Hayek SS, Sever S, Ko Y-A, et al. Soluble Urokinase Receptor and Chronic Kidney Disease. N Engl J Med, 2015, 373: 1916-1925.
[12] Krizhanovsky V, Yon M, Dickins RA, et al. Senescence of activated stellate cells limits liver fibrosis. Cell, 2008, 134: 657-667. |
